跳至主要内容
临床试验/ISRCTN17414946
ISRCTN17414946已完成1 期

A pilot study to evaluate the safety and efficacy of interferon beta-1a (IFN ß-1a) in the treatment of patients presenting with Ebola virus illness

Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)0 个研究点目标入组 50 人开始时间: 2016年7月19日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Able to provide informed consent (ubstitute decision maker may provide informed consent in cases where the patient is ill and unable to provide informed consent)
  • 2. Aged between 18 and 70 years on the day of inclusion
  • 3. In the treatment centre
  • 4. Confirmed ebola virus infection by RT-PCR
  • 5. Symptom onset < 6 days
  • 6. Able to comply with trial procedures

排除标准

  • 1. Known hypersensitivity to IFN ß preparations
  • 2. Pregnancy
  • 3. Chronic liver disease with synthetic dysfunction and/or decompensation, history of bleeding
  • 4. Moderate to severe congestive heart failure - grade III or IV left ventricular function
  • 5. Previous history of serious psychiatric illness
  • 6. History of sever or active autoimmune disease

研究者

发起方
Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)

相似试验

Interferon-ß treatment for Ebola virus disease | 临床试验